CTOs on the Move

Dyadic

www.dyadic.com

 
Dyadic uses its proprietary C1 platform technology to discover and develop novel genes and other biological products from eukaryotic organisms found in the full spectrum of the earth’s biodiversity. Once useful genes are isolated, Dyadic uses its integrated platform to manufacture specific proteins, doing so more rapidly and efficiently — and with a much higher rate of success than existing gene discovery systems. Dyadic leverages its proprietary technology platform to discover novel genes and biological products for use by its strategic partners, and to further its own R&D efforts. Dyadic seeks strategic alliances with major leaders in the agricultural, bioenergy, industrial enzyme, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.dyadic.com
  • 140 Intracoastal Pointe Dr Ste 404
    Jupiter, FL USA 33477
  • Phone: 561.743.8333

Executives

Name Title Contact Details

Similar Companies

Luknova

Luknova is a Mansfield, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenBio

ormed in 1994, GenBio is an experienced, fully integrated medical diagnostic company focused on infectious disease and autoimmune disease diagnostics. GenBio develops, manufactures and markets extensive lines of infectious disease and autoimmunity

Chelsea Therapeutics

Chelsea Therapeutics is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Evozyne

Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.

Aurion Biotech

With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. The Company`s first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.